Rhythm Pharma's obesity drug fails to meet main goal in late-stage trial
16/03/2026 20:05
March 16 (Reuters) - Rhythm Pharmaceuticals RYTM.O said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Alan Barona) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand